• Je něco špatně v tomto záznamu ?

Toxicities of PARP inhibitors in genitourinary cancers

J. Szalontai, T. Szarvas, M. Miszczyk, P. Nyirády, SF. Shariat, T. Fazekas

. 2025 ; 35 (4) : 467-471. [pub] 20250507

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015191

PURPOSE OF REVIEW: Recent advancements in the understanding of the genetic background of genitourinary cancers allowed for a successful introduction of targeted antitumor agents to prostate cancer (PCa) treatment. Inhibitors of the poly ADP-ribose polymerase enzyme (PARPi) transformed the treatment landscape of metastatic prostate cancer, and being increasingly studied in earlier disease stages. However, they are associated with nonnegligible toxicity, therefore, we aimed to summarize their side-effect profile in patients with PCa. RECENT FINDINGS: Hematologic toxicities, particularly anemia, thrombocytopenia, and neutropenia are among the most common and serious adverse events associated with PARPi, highlighting the need for regular blood count monitoring. Nonhematologic side effects, including fatigue, nausea, vomiting, diarrhea, and constipation, are common, and can be mitigated with supportive interventions like dietary modifications, antiemetics, or stool management techniques. Special attention should be given to patients with therapy-resistant or persistent cytopenia, in whom bone marrow biopsy should be considered, as it can indicate myelodysplastic syndrome and acute myeloid leukemia. SUMMARY: PARP inhibitors represent a major advancement in the management of metastatic prostate cancer, offering a significant survival benefit in applicable cases. However, patients need to be carefully selected and informed, to allow for optimal balancing between the benefits and nonneglectable risks of severe toxicities. Better understanding of PARPi toxicity profile can improve personalized decision-making and enhance treatment compliance, through raising patients' awareness about the possible side effects of PARPi.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015191
003      
CZ-PrNML
005      
20250731090822.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000001297 $2 doi
035    __
$a (PubMed)40336260
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Szalontai, János $u Department of Urology, Semmelweis University, Budapest, Hungary
245    10
$a Toxicities of PARP inhibitors in genitourinary cancers / $c J. Szalontai, T. Szarvas, M. Miszczyk, P. Nyirády, SF. Shariat, T. Fazekas
520    9_
$a PURPOSE OF REVIEW: Recent advancements in the understanding of the genetic background of genitourinary cancers allowed for a successful introduction of targeted antitumor agents to prostate cancer (PCa) treatment. Inhibitors of the poly ADP-ribose polymerase enzyme (PARPi) transformed the treatment landscape of metastatic prostate cancer, and being increasingly studied in earlier disease stages. However, they are associated with nonnegligible toxicity, therefore, we aimed to summarize their side-effect profile in patients with PCa. RECENT FINDINGS: Hematologic toxicities, particularly anemia, thrombocytopenia, and neutropenia are among the most common and serious adverse events associated with PARPi, highlighting the need for regular blood count monitoring. Nonhematologic side effects, including fatigue, nausea, vomiting, diarrhea, and constipation, are common, and can be mitigated with supportive interventions like dietary modifications, antiemetics, or stool management techniques. Special attention should be given to patients with therapy-resistant or persistent cytopenia, in whom bone marrow biopsy should be considered, as it can indicate myelodysplastic syndrome and acute myeloid leukemia. SUMMARY: PARP inhibitors represent a major advancement in the management of metastatic prostate cancer, offering a significant survival benefit in applicable cases. However, patients need to be carefully selected and informed, to allow for optimal balancing between the benefits and nonneglectable risks of severe toxicities. Better understanding of PARPi toxicity profile can improve personalized decision-making and enhance treatment compliance, through raising patients' awareness about the possible side effects of PARPi.
650    _2
$a lidé $7 D006801
650    12
$a PARP inhibitory $x škodlivé účinky $7 D000067856
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory prostaty $x farmakoterapie $x patologie $7 D011471
650    12
$a urogenitální nádory $x farmakoterapie $7 D014565
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Szarvas, Tibor $u Department of Urology, Semmelweis University, Budapest, Hungary $u Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany
700    1_
$a Miszczyk, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Collegium Medicum - Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland
700    1_
$a Nyirády, Péter $u Department of Urology, Semmelweis University, Budapest, Hungary
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Semmelweis University, Budapest, Hungary $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Research Centre for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan
700    1_
$a Fazekas, Tamás $u Department of Urology, Semmelweis University, Budapest, Hungary $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 35, č. 4 (2025), s. 467-471
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40336260 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090816 $b ABA008
999    __
$a ok $b bmc $g 2366194 $s 1252316
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 35 $c 4 $d 467-471 $e 20250507 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace